CHC Healthcare Group announced yesterday (13th) that its medical equipment distribution business has adjusted pricing in response to new product models, along with strong order growth, driving an unseasonably strong first quarter with an annual growth rate expected to reach 30%. The company anticipates quarterly revenue increases throughout the year, with double-digit annual revenue growth, setting new records in both revenue and profit.
This year, CHC Healthcare is also launching several new initiatives, including the development of a medical park on its own land in Yangmei, with construction expected to begin as early as the second quarter. The park will include a residential long-term care facility and a local hospital, marking CHC’s official expansion into long-term care services, with completion targeted for 2027. Meanwhile, its Fukang Pharmacy chain has grown to 60 locations and aims to expand to 80 stores by the end of the year and surpass 100 stores next year. The company is also preparing for Fukang Pharmacy’s IPO, with preliminary work already underway, and expects to enter the capital market by 2027.
CHC Healthcare’s stock closed at NT$54.6 yesterday, up NT$2.7. While January revenue declined 11.7% year-over-year due to fewer working days during the Lunar New Year holiday, growth momentum is expected to pick up starting in February and March.
CHC Healthcare noted that, in addition to strong demand for medical equipment, the company also expects its Miaoli irradiation facility, which began operations in the second half of last year, to see increased demand for medical materials this year. In the first half of the year, several semiconductor and aerospace-related clients are scheduled for testing and verification, with potential volume expansion in the second half, which will contribute to the facility’s profitability in 2024.
CHC Healthcare’s pharmacy business is also making strides. Fukang Pharmacy acquired "Happy Pharmacy", a local Hsinchu-based chain, last year, adding 10 new locations. Previously, Fukang Pharmacy’s stores were concentrated in Taipei, New Taipei, and Keelung, but this marks its first entry into Hsinchu. This year, CHC plans to identify new acquisition targets in central and southern Taiwan to further expand its scale.
CHC Healthcare stated that Fukang Pharmacy’s annual revenue surpassed NT$1 billion last year, and with continued expansion, it expects double-digit revenue growth this year. As the chain pharmacy sector continues to consolidate, CHC aims to secure a leading position in the industry by entering the capital market. The company has already begun internal audits and control measures, moving steadily toward its IPO goal.
Resource: 承業醫今年營收拚新高
